Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study

被引:2
作者
Arai, Yusuke [1 ]
Takahashi, Hidenori [1 ]
Inoda, Satoru [1 ]
Sakamoto, Shinichi [1 ]
Tan, Xue [2 ]
Kawashima, Hidetoshi [1 ]
Yanagi, Yasuo [3 ]
机构
[1] Jichi Med Univ, Dept Ophthalmol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[2] Japan Community Hlth Care Org Tokyo Shinjuku Med C, 5-1 Tsukudocho,Shinjuku Ku, Tokyo 1628543, Japan
[3] Yokohama City Univ, Dept Ophthalmol & Microtechnol, 4-57 Urafunecho,Minami Ku, Yokohama, Kanagawa 2320023, Japan
关键词
central retinal vein occlusion; anti-vascular endothelial growth factor; modified treat-and-extend regimen; personalized therapy; prospective multicenter intervention study; ANTI-VEGF TREATMENT; INTRAVITREAL AFLIBERCEPT; SUSTAINED BENEFITS; RANIBIZUMAB; OUTCOMES; DEGENERATION; SECONDARY; INJECTION;
D O I
10.3390/jcm12155089
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This prospective, multicentre, interventional study evaluated the efficacy of a modified treat-and-extend (mTAE) aflibercept regimen as personalized therapy for macular oedema (MO) due to central retinal vein occlusion (CRVO). Fifty eyes were studied from 50 patients who were enrolled between November 2016 and July 2019. All patients received intravitreal aflibercept (IVA) injections on an mTAE regimen for 24 months. Primary outcome measures were best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 12 months. Secondary endpoints were BCVA and CST at 24 months. Mean (standard deviation) baseline BCVA (logMAR) and CST were 0.50 (0.51) and 557 (240) & mu;m, respectively. BCVA and CST showed significant improvements at month 12 (0.19 (0.38) and 275 (98) & mu;m, respectively; both p < 0.0001, paired t-test). BCVA and CST also showed significant improvements at 24 months (0.26 (0.50) and 255 (91) & mu;m, respectively, p = 0.0004 and p < 0.0001, paired t-test). The mean numbers of IVA injections and clinic visits over the 24-month study period were 6.2 (3.0) and 10.3 (1.0), respectively. The mTAE regimen of IVA injections for MO due to CRVO was effective in improving BCVA and decreasing CST at 24 months. The mTAE regimen might be an effective personalized therapy for CRVO.
引用
收藏
页数:11
相关论文
共 50 条
[41]   Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab [J].
Konidaris, Vasileios ;
Al-Hubeshy, Zahra ;
Tsaousis, Konstantinos T. ;
Gorgoli, Konstantina ;
Banerjee, Somnath ;
Empeslidis, Theodoros .
INTERNATIONAL OPHTHALMOLOGY, 2018, 38 (01) :207-213
[42]   Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration [J].
Matsumoto, Hidetaka ;
Hiroe, Takashi ;
Morimoto, Masahiro ;
Mimura, Kensuke ;
Ito, Arisa ;
Akiyama, Hideo .
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2018, 62 (02) :144-150
[43]   Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration [J].
Ito, Arisa ;
Matsumoto, Hidetaka ;
Morimoto, Masahiro ;
Mimura, Kensuke ;
Akiyama, Hideo .
OPHTHALMOLOGICA, 2017, 238 (04) :236-242
[44]   Five-year outcome of aflibercept intravitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: Results from a prospective observational study [J].
Charles, Jarret ;
Chau, Tran Thi Ha .
TAIWAN JOURNAL OF OPHTHALMOLOGY, 2023, 13 (02) :219-224
[45]   Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab [J].
Spooner, Kimberly ;
Fraser-Bell, Samantha ;
Hong, Thomas ;
Chang, Andrew .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 48 (01) :53-60
[46]   A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration [J].
Masayuki Ohnaka ;
Yoshimi Nagai ;
Kenichiro Sho ;
Katsuaki Miki ;
Motoki Kimura ;
Tomoyuki Chihara ;
Kanji Takahashi .
Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 :657-664
[47]   EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION [J].
Lotfy, Ayman ;
Solaiman, Kamal A. M. ;
Abdelrahman, Ayman ;
Samir, Ahmed .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (09) :1795-1800
[48]   Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy [J].
Huang, Chu-Hsuan ;
Lai, Tso-Ting ;
Yang, Chang-Hao ;
Hsieh, Yi-Ting .
OPHTHALMOLOGY AND THERAPY, 2024, 13 (01) :385-396
[49]   Intravitreal Aflibercept (Eylea®): A Review of Its Use in Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion [J].
Lily P. H. Yang ;
Kate McKeage .
Drugs & Aging, 2014, 31 :395-404
[50]   Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab [J].
Vasileios Konidaris ;
Zahra Al-Hubeshy ;
Konstantinos T. Tsaousis ;
Konstantina Gorgoli ;
Somnath Banerjee ;
Theodoros Empeslidis .
International Ophthalmology, 2018, 38 :207-213